The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, efficacy safety this drug in treating other complement-related renal diseases not yet elucidated. high cost eculizumab therapy rare adverse effects have created a paradox conducting large clinical trials. There...